ERNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ernexa Therapeutics Inc (ERNA) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows weak financial performance, no positive trading signals, no recent positive news, and a bearish technical trend. Additionally, there are no significant catalysts or favorable trading trends to support a buy decision.
The technical indicators for ERNA are bearish. The MACD histogram is negative and contracting, the RSI is neutral at 27.92, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with a pivot at 0.493 and current price at 0.3597, suggesting further downside potential.
NULL identified. There is no recent news, no significant hedge fund or insider trading activity, and no recent congress trading data.
The company reported a significant decline in financial performance in Q3 2025, with revenue dropping to 0 (-100% YoY), net income dropping to -$1,240,000 (-95.34% YoY), and EPS dropping to -0.15 (-99.80% YoY). Gross margin also dropped to 0 (-100% YoY). Additionally, the stock is expected to decline further based on candlestick pattern analysis.
Ernexa Therapeutics Inc reported extremely poor financial results for Q3 2025. Revenue, net income, EPS, and gross margin all experienced significant declines, indicating a lack of growth and profitability.
No analyst rating or price target data available.
